With improvements in overall health attributable to newly available medications called highly effective modulator therapy, an increasing number of people with cystic fibrosis (CF) are pursuing pregnancy. However, the safety of these medications for pregnant people with CF and the fetus remains largely unknown. Limited data demonstrate a decline in patients' health and well-being after withdrawal of highly effective modulator therapy during pregnancy; however, both animal and human studies suggest an association between highly effective modulator therapy and cataracts in the offspring that requires further investigation. Use of highly effective modulator therapy can also affect the results of newborn screening and may influence fetal outcomes among fetuses affected by CF as a result of transplacental passage of highly effective modulator therapy. An ongoing prospective cohort study will likely provide more information for pregnant people with CF. Until then, multidisciplinary counseling continues to be critical for people with CF who are of reproductive age.

中文翻译：

---

接受高效调节剂治疗的囊性纤维化患者的妊娠。


随着称为高效调节剂疗法的新可用药物改善了整体健康状况，越来越多的囊性纤维化 （CF） 患者正在寻求怀孕。然而，这些药物对 CF 孕妇和胎儿的安全性在很大程度上仍然未知。有限的数据表明，在怀孕期间停用高效调节剂治疗后，患者的健康状况和福祉下降;然而，动物和人类研究表明，高效调节剂治疗与后代白内障之间存在关联，需要进一步研究。使用高效调节剂治疗也会影响新生儿筛查的结果，并可能影响因高效调节剂治疗经胎盘而受 CF 影响的胎儿的结局。一项正在进行的前瞻性队列研究可能会为 CF 孕妇提供更多信息。在此之前，多学科咨询对于育龄 CF 患者仍然至关重要。